R
Roche
Swiss multinational healthcare company that operates worldwide under two divisions: Pharmaceuticals and Diagnostics
About Roche
In 1896, Fritz Hoffmann-La Roche founded F. Hoffmann-La Roche & Co. in Basel, Switzerland. Initially, the company focused on producing vitamin preparations and derivatives, quickly gaining a reputation for quality and innovation.
One of Roche's early milestones was in 1934 when it became the first company to mass-produce synthetic vitamin C, branded as Redoxon. This achievement not only marked a significant advancement in the pharmaceutical industry but also set the stage for Roche's future growth.
Throughout the 20th century, Roche expanded its portfolio and global presence, navigating the complexities of the pharmaceutical landscape. The company made strategic acquisitions and investments, which bolstered its research capabilities and market reach.
A pivotal moment in Roche's history came in 2008 when it fully acquired Genentech, a leading biotechnology company. This acquisition was a strategic move to strengthen Roche's position in the biotechnology sector and enhance its research and development capabilities.
Today, Roche is recognized as a global leader in pharmaceuticals and diagnostics, committed to advancing healthcare through innovative solutions. The company's journey from a small vitamin producer to a major player in the global pharmaceutical industry is a testament to its enduring commitment to innovation and excellence.
Source: Dealroom company dataAt a glance
- Status
- Listed
- Founded
- 1896
- Headquarters
- Basel, Switzerland
- Listing
- IPO 2003
- Employees
- 1
- Open positions
- None listed
- Dealroom signal
- 29.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical
- Sector
- Biotech & Life Sciences, Testing, Biotechnology, Oncology, Horizon Europe, medical testing
- Business model
- Manufacturing
- Client focus
- b2b
- Investment activity
- 36 companies, latest May 2026
- Capital deployed
- $424M
- Preferred round
- ACQUISITION
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| POST IPO DEBT✓Debt | Mar 2026 | $7.5B | — | Deutsche Bank | ↗ |
| POST IPO DEBT✓Debt | Dec 2025 | $1.9B | — | Simpson Thacher & Bartlett | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for Roche is 1.2M monthly website visits, down 7.7% over the last three months. Roche's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
PathAIBoston, United StatesAI-powered pathology platform optimizing diagnostic accuracy and research
$660Mvaluation
SAGAMorrisville, United StatesProviding cancer companion diagnostic testing of tissue and non-invasive monitoring of circulating tumor DNA (ctDNA)
$46Mvaluation
FreenomeBrisbane, United StatesA health technology company developing accurate, accessible and non-invasive disease screening products
$1.8Bvaluation
89bioSan Francisco, United StatesA biopharmaceutical company building a pipeline of biologic and small molecule treatments for liver and metabolic disorders
$1.7Bvaluation
Poseida TherapeuticsSan Diego, United StatesPoseida Therapeutics utilizes best-in-class genome engineering capabilities to develop targeted lifesaving therapeutics
$778Mvaluation
Carmot TherapeuticsSan Francisco, United StatesDedicated to the discovery and development of innovative medicines
$2.7Bvaluation
TelavantNew York City, United StatesCompany, is developing innovative therapies to
$7.1Bvaluation
Belharra TherapeuticsSan Diego, United StatesBelharra Therapeutics is the next generation of small molecule discovery - a company founded by the pioneers of the field of chemical biology
$200Mvaluation
Good TherapeuticsSeattle, United StatesDevelops new technology for self-regulating drugs that will provide a therapeutic activity when, where it is needed
$55Mvaluation
Tib MolbiolBerlin, GermanyTIB MOLBIOL - Research for Life - TIB MOLBIOL
→
Sentient MedHerzliya, IsraelDigital healthcare company focused on improving digital pathology and patients outcome
→
GenMark DiagnosticsCarlsbad, United StatesLeading provider of automated, multiplex molecular diagnostic testing systems
$1.8Bvaluation
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series B and later4 investors entered at this stage
SCALE AI
SoftBank
Simpson Thacher & Bartlett
Deutsche Bank
Other known investors8 additional known investors
Sofinnova Investments
5AM Ventures
Droia Oncology Ventures
Gilde Healthcare
Novi Management
Quest for Growth
US Biomedical Advanced Research and Development Authority
Wellington Partners
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Roche on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Roche’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.